Virpax Pharmaceuticals, Inc. has filed an amended Current Report on Form 8-K/A with the SEC, addressing the resignation of Gerald Bruce as a director and denying allegations made in his resignation letter. The company also received a deficiency notice from Nasdaq on October 4, 2024, for not meeting the minimum bid price requirement of $1.00 per share over the last 30 consecutive business days. Virpax has until April 2, 2025, to regain compliance or face potential delisting. Additionally, on October 5, 2024, CEO Gerald Bruce and CFO Vinay Shah resigned due to disagreements with the Board's policies and practices. The following day, Jatinder Dhaliwal was appointed as the new CEO and Katharyn Field took over Dhaliwal's position on the audit committee.

Virpax Pharmaceuticals, Inc. has filed an amended Current Report on Form 8-K/A with the SEC, addressing the resignation of Gerald Bruce as a director and denying allegations made in his resignation letter. The company also received a deficiency notice from Nasdaq on October 4, 2024, for not meeting the minimum bid price requirement of $1.00 per share over the last 30 consecutive business days. Virpax has until April 2, 2025, to regain compliance or face potential delisting. Additionally, on October 5, 2024, CEO Gerald Bruce and CFO Vinay Shah resigned due to disagreements with the Board's policies and practices. The following day, Jatinder Dhaliwal was appointed as the new CEO and Katharyn Field took over Dhaliwal's position on the audit committee.